Rosemarie Foronda, APRN
Nurse Practitioner · Wailuku, HINPI 1154346914
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Insulet Corporation at 48.3% of the total. Reporting peaked in 2023 at $8,433 and has fallen 84.9% since, to $1,272 in 2025. Among nurse practitioner clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $43.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$7K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Bayer$895
- AstraZeneca$635
- Boehringer Ingelheim$582
- plus $2K from 12 others
Across 4 payments — averaging $748.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$3K
What the payments were for
- Speaking & faculty fees$7,20048%
- Food & beverage$7,77952%
- Education$490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 15 | $7,252 |
| Novo Nordisk | 95 | $2,220 |
| Lilly USA, LLC | 68 | $1,518 |
| Bayer | 41 | $895 |
| AstraZeneca | 25 | $635 |
| Boehringer Ingelheim | 29 | $582 |
| Mannkind Corporation | 18 | $368 |
| Sanofi-aventis U.S. LLC | 19 | $362 |
| Merck | 13 | $218 |
| Dexcom, Inc. | 4 | $218 |
| Johnson & Johnson | 2 | $180 |
| Corcept Therapeutics | 7 | $151 |
| Terumo Medical Corporation | 1 | $125 |
| Boston Scientific | 1 | $125 |
| Abbott | 6 | $111 |
| Tandem Diabetes Care, Inc. | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$7,200
- RYBELSUS$432
- Ozempic$235
- Kerendia$224
- DEXCOM G7 GSS (161)$156
- DEXCOM STELO GLUCOSE BIOSENSOR$156
- GENERAL ATHERECTOMY$125
- FARXIGA$124
- MOUNJARO$124
- XARELTO$122
- Wegovy$108
How this compares
$15,029 in reported general payments places this provider in the 95th percentile of 215 nurse practitioner providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 354 | $539,215 |
| MounjaroTirzepatide | 219 | $326,967 |
| JardianceEmpagliflozin | 198 | $283,345 |
| TrulicityDulaglutide | 156 | $247,348 |
| RybelsusSemaglutide | 64 | $122,760 |
| FarxigaDapagliflozin Propanediol | 101 | $100,180 |
| JanuviaSitagliptin Phosphate | 41 | $52,335 |
| Tresiba Flextouch U-100Insulin Degludec | 88 | $50,130 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 30 | $48,159 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 79 | $35,249 |
| AfrezzaInsulin Regular, Human | 12 | $34,227 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $31,572 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $23,169 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 179 | $22,841 |
| Novolog FlexpenInsulin Aspart | 73 | $20,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,220 | $667,984436 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30 | $1,518 | $579,282404 claims |
| Boehringer IngelheimJardiance | $582 | $283,345198 claims |
| AstraZenecaFarxiga | $635 | $100,180101 claims |
| MerckJanuvia | $218 | $52,33541 claims |
| Mannkind CorporationAfrezza | $368 | $34,22712 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $362 | $29,09855 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 nurse practitioner providers in Hawaii.
Other nurse practitioner in Wailuku
- Ralph DomingoWailuku$2K
- Kirsten JensenWailuku$791
- Kimi PrenticeEwa Beach$65K
- Ashley SpringerHonolulu$43K
- Sung JungHonolulu$29K
- Judy KoHonolulu$17K
- Joanna AgenaAiea$16K
- Bryce MontalboHonolulu$15K
- Anitalei AlexioAiea$11K
- Rita AbreuHonolulu$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.